Pawel Muranski

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11458805/publications.pdf

Version: 2024-02-01

56	9,673	126858	168321
papers	citations	33 h-index	53 g-index

56	56	56	13133
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy. New England Journal of Medicine, 2019, 380, 1597-1605.	13.9	260
2	Over-expression of PD-1 Does Not Predict Leukemic Relapse after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 216-222.	2.0	11
3	Distinct Biomarker Profiles in Ex Vivo T Cell Depletion Graft Manipulation Strategies: CD34+ Selection versus CD3+/19+ Depletion in Matched Sibling Allogeneic Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 460-466.	2.0	3
4	Activation of Th1 Immunity within the Tumor Microenvironment Is Associated with Clinical Response to Lenalidomide in Chronic Lymphocytic Leukemia. Journal of Immunology, 2018, 201, 1967-1974.	0.4	22
5	Ex vivo T-cellâ€“depleted allogeneic stem cell transplantation for hematologic malignancies: The search for an optimum transplant T-cell dose and T-cell add-back strategy. Cytotherapy, 2017, 19, 735-743.	0.3	5
6	Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia. Leukemia Research Reports, 2017, 7, 40-44.	0.2	5
7	A subset of virus-specific CD161+ T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML. Blood, 2017, 129, 740-758.	0.6	35
8	T cell therapies for human polyomavirus diseases. Cytotherapy, 2017, 19, 1302-1316.	0.3	17
9	Rapamycin is highly effective in murine models of immune-mediated bone marrow failure. Haematologica, 2017, 102, 1691-1703.	1.7	42
10	Adenosine Selectively Depletes Alloreactive T Cells to Prevent GVHD While Conserving Immunity to Viruses and Leukemia. Molecular Therapy, 2016, 24, 1655-1664.	3.7	8
11	PPARÂ antagonist attenuates mouse immune-mediated bone marrow failure by inhibition of T cell function. Haematologica, 2016, 101, 57-67.	1.7	20
12	Memory Stem T Cells in Autoimmune Disease: High Frequency of Circulating CD8+ Memory Stem Cells in Acquired Aplastic Anemia. Journal of Immunology, 2016, 196, 1568-1578.	0.4	74
13	Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy. Cell Metabolism, 2016, 23, 63-76.	7.2	291
14	Safety and Feasibility of Ultra-Low Dose IL-2 As Graft Versus Host Disease Prophylaxis in Haplo-Identical Stem Cell Transplantation- a Proof of Concept Pilot Study. Blood, 2016, 128, 386-386.	0.6	0
15	Identification of novel microRNA signatures linked to acquired aplastic anemia. Haematologica, 2015, 100, 1534-1545.	1.7	29
16	Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells. Stem Cell Research, 2015, 14, 95-104.	0.3	48
17	Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics. Cancer Research, 2015, 75, 296-305.	0.4	283
18	Clinical and biological predictors of outcome following relapse of CML post-allo-SCT. Bone Marrow Transplantation, 2015, 50, 189-196.	1.3	7

#	Article	IF	Citations
19	Memory T cellâ€“driven differentiation of naive cells impairs adoptive immunotherapy. Journal of Clinical Investigation, 2015, 126, 318-334.	3.9	193
20	Selective Depletion of Alloreactive Donor T Cells with Adenosine: An Efficient, Scaleable, GMP-Compliant, Low-Cost Method to Prevent Gvhd While Preserving Antiviral and Antileukemic Activity in Haploidentical Stem Cell Transplant. Blood, 2015, 126, 380-380.	0.6	2
21	High Frequency of Circulating CD8+ Memory Stem T Cells in Acquired Aplastic Anemia. Blood, 2015, 126, 3613-3613.	0.6	0
22	Timing and intensity of exposure to interferonâ€Î³ critically determines the function of monocyteâ€derived dendritic cells. Immunology, 2014, 143, 96-108.	2.0	13
23	An easy way to make a good anti-tumor chimeric antigen receptor TÂcell?. Cytotherapy, 2014, 16, 577-578.	0.3	0
24	Genetically engineered fixed K562 cells: potent â€œoff-the-shelfâ€•antigen-presenting cells for generating virus-specific T cells. Cytotherapy, 2014, 16, 135-146.	0.3	4
25	The clinical and financial burden of pre-emptive management ofÂcytomegalovirus disease after allogeneic stem cell transplantationâ€”implications for preventative treatment approaches. Cytotherapy, 2014, 16, 927-933.	0.3	56
26	Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers. Molecular Therapy, 2014, 22, 1388-1395.	3.7	106
27	Ex Vivo Generation of CD4+ Th17 Cells to Prevent and Treat Infection from Antibiotic-Resistant Klebsiella Pneumoniae in Immunocompromised Patients. Blood, 2014, 124, 2445-2445.	0.6	1
28	Essentials of Th17 cell commitment and plasticity. Blood, 2013, 121, 2402-2414.	0.6	306
29	Retinoic acid controls the homeostasis of pre-cDCâ€“derived splenic and intestinal dendritic cells. Journal of Experimental Medicine, 2013, 210, 1961-1976.	4.2	120
30	Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. Journal of Clinical Investigation, 2013, 123, 4479-4488.	3.9	719
31	Myeloid Leukemias Directly Suppress T Cell Proliferation Through STAT3 and Arginase Pathways. Blood, 2013, 122, 3885-3885.	0.6	5
32	Alemtuzumab Achieved Durable Hematologic Response In Heavily Treated T-Large Granular Lymphocytosis Irrespective To STAT3 Mutation Or V-Beta Clone Size. Blood, 2013, 122, 3705-3705.	0.6	1
33	Ex Vivo Generation Of CD4+ T Cells To Prevent and Treat Infection From Antibiotic-Resistant Klebsiella Pneumoniae In Immunocompromised Patients. Blood, 2013, 122, 2022-2022.	0.6	1
34	Ultra-Low Dose IL-2 Safely Expands Regulatory T Cells and CD56bright NK Cells in Healthy Volunteers: Towards Safer Stem Cell Donors?. Blood, 2012, 120, 3283-3283.	0.6	2
35	Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells. Nature Immunology, 2011, 12, 1230-1237.	7.0	165
36	Th17 Cells Are Long Lived and Retain a Stem Cell-like Molecular Signature. Immunity, 2011, 35, 972-985.	6.6	392

#	Article	IF	Citations
37	Genetic Engineering of Murine CD8+ and CD4+ T Cells for Preclinical Adoptive Immunotherapy Studies. Journal of Immunotherapy, 2011, 34, 343-352.	1.2	80
38	Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood, 2011, 117, 808-814.	0.6	272
39	Determinants of Successful CD8+ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice. Clinical Cancer Research, 2011, 17, 5343-5352.	3.2	247
40	IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. Journal of Clinical Investigation, 2011, 121, 4746-4757.	3.9	283
41	Increased Intensity Lymphodepletion Enhances Tumor Treatment Efficacy of Adoptively Transferred Tumor-specific T Cells. Journal of Immunotherapy, 2010, 33, 1-7.	1.2	236
42	Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma. Journal of Experimental Medicine, 2010, 207, 651-667.	4.2	389
43	Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. Journal of Experimental Medicine, 2010, 207, 637-650.	4.2	715
44	Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts. Cancer Research, 2010, 70, 6725-6734.	0.4	227
45	Adoptively transferred effector cells derived from naÃ¯ve rather than central memory CD8 ⁺ T cells mediate superior antitumor immunity. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 17469-17474.	3.3	348
46	Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nature Medicine, 2009, 15, 808-813.	15.2	839
47	Adoptive immunotherapy of cancer using CD4+ T cells. Current Opinion in Immunology, 2009, 21, 200-208.	2.4	202
48	T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity. Immunity, 2009, 31, 787-798.	6.6	679
49	Type 17 CD8+ T cells display enhanced antitumor immunity. Blood, 2009, 114, 596-599.	0.6	196
50	Does IL-17 promote tumor growth?. Blood, 2009, 114, 231-232.	0.6	26
51	Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. Blood, 2008, 112, 4746-4754.	0.6	39
52	Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood, 2008, 112, 362-373.	0.6	719
53	Toll-like Receptors in Tumor Immunotherapy. Clinical Cancer Research, 2007, 13, 5280-5289.	3.2	114
54	Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. Journal of Clinical Investigation, 2007, 117, 2197-2204.	3.9	456

#	Article	IF	Citations
55	Increased intensity lymphodepletion and adoptive immunotherapyâ€"how far can we go?. Nature Clinical Practice Oncology, 2006, 3, 668-681.	4.3	318
56	Mature CD4+ T Cells Perceive a Positively Selecting Class II MHC/Peptide Complex in the Periphery. Journal of Immunology, 2000, 164, 3087-3094.	0.4	42